Cell Therapy for Diabetic Nephropathy: Is the Future, Now?

Seminars in Nephrology

Volumn 32, Issue 5, 2012, Pages 486-493

  Gilbert, Richard E ^a   Zhang, Yanling ^a   Yuen, Darren A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; AVE 9488; CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DIETHYLENETRIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE DONOR; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ACUTE HEART INFARCTION; ANGIOGENESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL THERAPY; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXERCISE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; STEM CELL MOBILIZATION; THERAPY EFFECT;

ANIMALS; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE THERAPY;

EID: 84867373791     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.07.012     Document Type: Article

References (67)

1. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
2. Baumgartner-Parzer S.M., Wagner L., Pettermann M., et al. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 1995, 44:1323-1327.
3. Ho F.M., Liu S.H., Liau C.S., et al. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000, 101:2618-2624.
4. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996, 97:2883-2890.
5. Frustaci A., Kajstura J., Chimenti C., et al. Myocardial cell death in human diabetes. Circ Res 2000, 87:1123-1132.
6. Isermann B., Vinnikov I.A., Madhusudhan T., et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007, 13:1349-1358.
7. Mauer S., Steffes M., Ellis E., et al. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984, 74:1143-1155.
8. Lindenmeyer M.T., Kretzler M., Boucherot A., et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007, 18:1765-1776.
9. Laplante P., Sirois I., Raymond M.A., et al. Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis. Cell Death Differ 2010, 17:291-303.
10. Bohle A., Mackensen-Haen S., Wehrmann M. Significance of postglomerular capillaries in the pathogenesis of chronic renal failure. Kidney Blood Press Res 1996, 19:191-195.
11. Bader R., Bader H., Grund K.E., et al. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract 1980, 167:204-216.
12. Gilbert R.E., Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int 1999, 56:1627-1637.
13. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
14. Langham R.G., Kelly D.J., Cox A.J., et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002, 45:1572-1576.
15. Advani A., Gilbert R.E. The endothelium in diabetic nephropathy. Semin Nephrol 2012, 32:199-207.
16. Risau W., Sariola H., Zerwes H.G., et al. Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 1988, 102:471-478.
17. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
18. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
19. Richardson M.R., Yoder M.C. Endothelial progenitor cells: quo vadis?. J Mol Cell Cardiol 2011, 50:266-272.
20. Hur J., Yoon C.H., Kim H.S., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24:288-293.
21. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
22. Urbich C., De Souza A.I., Rossig L., et al. Proteomic characterization of human early pro-angiogenic cells. J Mol Cell Cardiol 2011, 50:333-336.
23. Psaltis P.J., Zannettino A.C., Worthley S.G., et al. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008, 26:2201-2210.
24. Bababeygy S.R., Cheshier S.H., Hou L.C., et al. Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture. Stem Cells Dev 2008, 17:11-18.
25. Mirotsou M., Jayawardena T.M., Schmeckpeper J., et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011, 50:280-289.
26. Bi B., Schmitt R., Israilova M., et al. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007, 18:2486-2496.
27. Yuen D.A., Connelly K.A., Advani A., et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 2010, 5:e9543.
28. Egan C.G., Lavery R., Caporali F., et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008, 51:1296-1305.
29. Fadini G.P., Boscaro E., de Kreutzenberg S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010, 33:1097-1102.
30. Loomans C.J., de Koning E.J., Staal F.J., et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53:195-199.
31. Dessapt C., Karalliedde J., Hernandez-Fuentes M., et al. Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care 2010, 33:875-877.
32. Makino H., Okada S., Nagumo A., et al. Decreased circulating CD34+ cells are associated with progression of diabetic nephropathy. Diabet Med 2009, 26:171-173.
33. Fadini G.P., Sartore S., Schiavon M., et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006, 49:3075-3084.
34. Boyle A.J., Whitbourn R., Schlicht S., et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol 2006, 109:21-27.
35. Segal M.S., Shah R., Afzal A., et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006, 55:102-109.
36. Assmus B., Schachinger V., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
37. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7.
38. Werner N., Kosiol S., Schiegl T., et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005, 353:999-1007.
39. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
40. Abdel-Latif A., Bolli R., Tleyjeh I.M., et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007, 167:989-997.
41. Yousef M., Schannwell C.M., Kostering M., et al. The BALANCE study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009, 53:2262-2269.
42. Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 2011, 50:258-265.
43. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
44. Assmus B., Rolf A., Erbs S., et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ Heart Fail 2010, 3:89-96.
45. Abdel-Latif A., Bolli R., Zuba-Surma E.K., et al. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2008, 156:216-226. e219.
46. Zaruba M.M., Theiss H.D., Vallaster M., et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009, 4:313-323.
47. Steinhauser M.L., Lee R.T. Cardiovascular regeneration: pushing and pulling on progenitors. Cell Stem Cell 2009, 4:277-278.
48. Fadini G.P., Boscaro E., Albiero M., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:7-1609.
49. Larochelle A., Krouse A., Metzger M., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006, 107:3772-3778.
50. Williams-Herman D., Round E., Swern A.S., et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
51. Frederich R., Alexander J.H., Fiedorek F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
52. Gallwitz B, Uhlig-Laske G, Bhattacharaya S. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin [abstract 0039-LB]. Proceedings of the American Diabetes Association; Alexandria, VA, 2011.
53. Johansen O, Neubacher D, von Eynatten M. Cardiovascular risk with linagliptin in patients with type 2 diabetes: a pre-specified, prospective, and adjudicated meta-analysis from a large phase III program [abstract 0030-LB]. Proceedings of the American Diabetes Association; Alexandria, VA, 2011.
54. Gallagher K.A., Liu Z.J., Xiao M., et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007, 117:1249-1259.
55. Segers V.F., Tokunou T., Higgins L.J., et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007, 116:1683-1692.
56. Saxena A., Fish J.E., White M.D., et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008, 117:2224-2231.
57. Hu X., Dai S., Wu W.J., et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007, 116:654-663.
58. Sasaki K., Heeschen C., Aicher A., et al. Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A 2006, 103:14537-14541.
59. Wu L., Cox A., Roe C., et al. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997, 51:1553-1567.
60. Amann K., Breitbach M., Ritz E., et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998, 9:1018-1022.
61. Amann K., Wiest G., Zimmer G., et al. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 1992, 42:1079-1085.
62. Zhang Y., Yuen D.A., Advani S.L., et al. Early outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes 2012, 61:2114-2125.
63. Hare J.M., Traverse J.H., Henry T.D., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54:2277-2286.
64. Losordo D.W., Schatz R.A., White C.J., et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation 2007, 115:3165-3172.
65. Gilbert R.E., Tsalamandris C., Allen T.J., et al. Early nephropathy predicts vision-threatening retinal disease in patients with type I diabetes mellitus. J Am Soc Nephrol 1998, 9:85-89.
66. Bressler N.M., Beck R.W., Ferris F.L. Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med 2011, 365:1520-1526.
67. Brunner S., Schernthaner G.H., Satler M., et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: first in vivo data. Invest Ophthalmol Vis Sci 2009, 50:392-398.